First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer

被引：0
|
作者：
Xie, Hui
Li, Wei
Yao, Yufeng
Ni, Sujie
Yi, Tongbo
Cheng, Jinling
Fang, Qi
Zhang, Lei
Zhou, Jun
Wu, Xiaohong
Wang, Chunbin
Zhang, Yanan
Qin, Jianwei
Shao, Qing
Zhao, Tao
Huang, Xiaohong
Xu, Lingyun
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-13-41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-13-41
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    [J]. GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [2] Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study
    Yao, De-Shun
    Wang, Wei
    Chang, Jin-Yi
    Zhang, Yang
    Zhang, Hui-Wen
    Xu, Jin-Xia
    Cai, Hai-Feng
    [J]. GLAND SURGERY, 2021, 10 (12) : 3362 - 3368
  • [3] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [4] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    [J]. Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [5] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    [J]. GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [6] Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
    Ricciardi, Giuseppina Rosaria Rita
    Franchina, Tindara
    Russo, Alessandro
    Schifano, Silvia
    Ferraro, Giuseppa
    Adamo, Vincenzo
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 4351 - 4355
  • [7] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [8] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Pier Paolo M. Berton Giachetti
    Giuseppe Curigliano
    [J]. Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
  • [9] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [10] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    [J]. CANCER RESEARCH, 2013, 73
12345